Impact of antiretroviral therapy interruption on plasma biomarkers of cardiovascular risk and lipids: 144-week final data from the STOPAR study

HIV Medicine

Volumn 13, Issue 8, 2012, Pages 488-498

  Olmo, M ^a   Saumoy, M ^a   Alonso Villaverde, C ^b   Penaranda M ^b   Gutierrez F ^c   Romeu, J ^d   Larrousse, M ^e   Curto, J ^a   Domingo, P ^f   Oteo, Ja ^g   Vila, A ^a   Podzamczer, D ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL SON LLÀTZER   (Spain)

^c MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g Hospital de La Rioja   (Spain)

Author keywords

Cardiovascular risk; CD4 guided treatment interruption; Monocyte chemotactic protein 1; Soluble vascular cell adhesion molecule 1

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT REFUSAL; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; CYTOKINES; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SPAIN; VIRAL LOAD;

EID: 84864304523     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2012.01000.x     Document Type: Article

References (27)

1. The Strategies for Management of Antirtroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
2. Ananworanich J, Gayet-Ageron A, Le Braz M etal. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368: 459-465.
3. Maggiolo F, Airoldi M, Callegaro A etal. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 2009; 23: 799-807.
4. Phillips AN, Carr A, Neuhaus J etal. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177-187.
5. Tebas P, Henry WK, Matining R etal. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE 2008; 3: e2021.
6. Lampe FC, Duprez DA, Kuller LH etal. Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54: 275-284.
7. Seoane E, Resino S, Micheloud D etal. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. J Acquir Immune Defic Syndr 2008; 48: 455-459.
8. Papasavvas E, Azzoni L, Pistilli M etal. Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule -1 levels following resumption of antiretroviral therapy. AIDS 2008; 22: 1153-1161.
9. Kuller LH, Tracy R, Belloso W etal. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
10. Calmy A, Gayet-Ageron A, Montecucco F etal. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23: 929-939.
11. Olmo M, Peñaranda M, Gutiérrez F etal. Estudio randomizado de interrupción de tratamiento guiada por CD4 en pacientes tratados mayoritariamente con inhibidores de la transcriptasa inversa no análogos de nucleósidos: resultado final a los 36 meses [PO-72]. I Congreso Nacional de Gesida. Madrid, Spain, October 2009.
12. Kamin DS, Grinspoon S. Cardiovascular disease in HIV-positive patients. AIDS 2005; 19: 641-652.
13. Torriani FJ, Komarow L, Parker RA etal. Endothelial function in HIV-infected antiretroviral naïve subjects before and after starting potent antiretroviral therapy: AIDS Clinical Trials Group Study 5152s. J Am Coll Cardiol 2008; 52: 569-576.
14. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10: 79-87.
15. Francisci D, Giannini S, Baldelli F etal. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS 2009; 23: 589-596.
16. Lowe GDO, Danesh J, Lewington S etal. Tissue plasminogen activator antigen and coronary heart disease. Eur Heart J 2004; 25: 252-259.
17. Heeschen C, Dimmeler S, Hamm CW etal. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111.
18. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-2179.
19. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456-462.
20. Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008; 56: 752-769.
21. Franco JM, Rubio A, Rey C etal. Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 1999; 18: 733-736.
22. Regidor DL, Detels R, Breen EC etal. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011; 25: 303-314.
23. Khovidhunkit W, Kim M-S, Memon RA etal. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196.
24. Joven J, Coll B, Tous M etal. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta 2006; 368: 114-119.
25. Aragonès G, Beltrán-Debón R, Rull A etal. Human immunodeficiency virus-infection induces major changes in high-density lipoprotein size distribution and composition: the effect of antiretroviral treatment and disease severity. Clin Chem Lab Med 2010; 48: 1147-1152.
26. Wang L, Chen W-Z, Wu M-P. Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index. Cytokine 2010; 49: 194-200.
27. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004; 318: 680-683.